Izrael - angličtina - Ministry of Health

boehringer ingelheim israel ltd. - ipratropium bromide - inhaler - ipratropium bromide 0.02 mg - ipratropium bromide - ipratropium bromide - for the relief of symptoms of reversible bronchospasm associated with asthma, chronic bronchitis and emphysema.

Spojené štáty - angličtina - NLM (National Library of Medicine)

jubilant draximage (usa) inc. - technetium tc-99m sestamibi (unii: 971z4w1s09) (technetium tc-99m sestamibi - unii:971z4w1s09) - tetrakis(2-methoxyisobutylisocyanide)copper(i) tetrafluoroborate 1 mg in 1 ml - myocardial imaging: kit for the preparation of technetium tc 99m sestamibi injection is a myocardial perfusion agent that is indicated for detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects), in evaluating myocardial function and developing information for use in patient management decisions. technetium tc 99m sestamibi evaluation of myocardial ischemia can be accomplished with rest and cardiovascular stress techniques (e.g., exercise or pharmacologic stress in accordance with the pharmacologic stress agents labeling). it is usually not possible to determine the age of a myocardial infarction or to differentiate a recent myocardial infarction from ischemia. breast imaging: kit for the preparation of technetium tc 99m sestamibi injection is indicated for planar imaging as a second line diagnostic drug after mammography to assist in the evaluation of breast lesions in patients with an abnormal mammogram or a palpable breast mass. kit f

Spojené kráľovstvo - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi - insulin human - solution for injection - 100unit/1ml

Spojené kráľovstvo - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi - insulin human - solution for injection - 100unit/1ml

Spojené štáty - angličtina - NLM (National Library of Medicine)

jubilant hollisterstier general partnership - technetium tc-99m sestamibi (unii: 971z4w1s09) (technetium tc-99m sestamibi - unii:971z4w1s09) - tetrakis(2-methoxyisobutylisocyanide)copper(i) tetrafluoroborate 1 mg in 10 ml

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

medtronic australasia pty ltd - 31744 - cardiovascular patch, synthetic - ptfe polymer oval pledgets are nonabsorbable, undyed fabrics composed of poly (tetrafluoroethylene). ptfe pledgets elicit a minimal acute inflammatory reaction in tissues, followed by gradual encapsulation of the fabric by fibrous connective tissue. ptfe pledgets are not absorbed, nor is any significant change in tensile strength retention known to occur in vivo. ptfe polymer oval pledgets are indicated for use as non-absorbable suture buttresses when there is a possibility of suture tearing through tissue. these pledgets are used in various surgical procedures such as vascular closure, septal repair, myocardial closure, valvular suturing and hepatic repair.

Izrael - angličtina - Ministry of Health

bayer israel ltd - radium-223 dichloride - solution for injection - radium-223 dichloride 1100 kbq/ml at reference date - radium (223 ra) dichloride - xofigo monotherapy or in combination with luteinising hormone releasing hormone (lhrh) analogue is indicated for the treatment of adult patients with metastatic castration-resistant prostate cancer (mcrpc), symptomatic bone metastases and no known visceral metastases, in progression after at least two prior lines of systemic therapy for advanced pc (other than lhrh analogues), or ineligible for any available systemic mcrpc treatment.

Izrael - angličtina - Ministry of Health

bayer israel ltd - radium-223 dichloride - solution for injection - radium-223 dichloride 1100 kbq/ml at reference date - radium (223 ra) dichloride - xofigo monotherapy or in combination with luteinising hormone releasing hormone (lhrh) analogue is indicated for the treatment of adult patients with metastatic castration-resistant prostate cancer (mcrpc), symptomatic bone metastases and no known visceral metastases, in progression after at least two prior lines of systemic therapy for advanced pc (other than lhrh analogues), or ineligible for any available systemic mcrpc treatment.

Izrael - angličtina - Ministry of Health

bayer israel ltd - radium-223 dichloride - solution for injection - radium-223 dichloride 1100 kbq/ml at reference date - radium (223 ra) dichloride - xofigo monotherapy or in combination with luteinising hormone releasing hormone (lhrh) analogue is indicated for the treatment of adult patients with metastatic castration-resistant prostate cancer (mcrpc), symptomatic bone metastases and no known visceral metastases, in progression after at least two prior lines of systemic therapy for advanced pc (other than lhrh analogues), or ineligible for any available systemic mcrpc treatment.

Izrael - angličtina - Ministry of Health

bayer israel ltd - radium-223 dichloride - solution for injection - radium-223 dichloride 1100 kbq/ml at reference date - radium (223 ra) dichloride - xofigo monotherapy or in combination with luteinising hormone releasing hormone (lhrh) analogue is indicated for the treatment of adult patients with metastatic castration-resistant prostate cancer (mcrpc), symptomatic bone metastases and no known visceral metastases, in progression after at least two prior lines of systemic therapy for advanced pc (other than lhrh analogues), or ineligible for any available systemic mcrpc treatment.